Check out our most popular compounded medications! Get Started
Description: This custom-compounded formulation combines bioidentical hormones estradiol (0.4 mg), estriol (1.6 mg), progesterone (50 mg), and testosterone (3 mg) into a single slow-release oral capsule. Utilizing Methocel E4M, a sophisticated controlled-release polymer, the capsules are engineered to deliver a steady, gradual release of hormones into the bloodstream. This method ensures sustained therapeutic levels, which can help in managing symptoms associated with menopause, hormone imbalances, and specific endocrine disorders. The slow-release mechanism also means fewer doses are needed, potentially enhancing patient adherence to the treatment regimen. These capsules are tailored to provide relief from hot flashes, night sweats, mood swings, decreased libido, and other hormone-related conditions, while also supporting overall hormonal health.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
The formulation in question combines bioidentical hormones estradiol, estriol, progesterone, and testosterone in specific doses to create a hormone replacement therapy (HRT) tailored for patients who may be experiencing symptoms associated with hormonal imbalances or deficiencies. Estradiol at 0.4 mg and estriol at 1.6 mg work synergistically to address estrogen deficiency, which can lead to menopausal symptoms such as hot flashes, night sweats, vaginal dryness, and osteoporosis. Progesterone at 50 mg is included to counterbalance estrogen and reduce the risk of endometrial hyperplasia, which can occur with estrogen therapy alone. Testosterone at 3 mg is added to support libido, muscle mass, and energy levels, which can be adversely affected by hormonal changes in both men and women.
The use of Methocel E4M, a hydrophilic methylcellulose derivative, in the capsule formulation allows for a slow-release mechanism. This controlled-release polymer ensures that the hormones are released gradually into the bloodstream over an extended period, mimicking the body's natural hormone release patterns more closely than immediate-release formulations. This slow-release profile can lead to more stable hormone levels, minimizing fluctuations that might cause side effects and improving overall efficacy of the therapy. Additionally, the reduced dosing frequency enhances patient compliance, as patients need to remember to take their medication less often.
This particular combination of hormones and the slow-release delivery system can be beneficial for patients with menopause-related symptoms, androgen deficiency, and other hormonal imbalances that require a comprehensive approach. It is important for prescribers to consider individual patient needs, including their specific symptoms, hormone levels, and risk factors, when determining the appropriateness of this HRT formulation. Monitoring and adjusting the therapy may be necessary to achieve optimal results and minimize potential risks associated with hormone replacement therapy.
For patients and prescribers interested in this formulation, it is crucial to engage in a thorough discussion about the potential benefits and risks, as well as the patient's medical history and current health status. If you have any questions or require further information about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is dedicated to providing personalized care and support to ensure the best possible outcomes for our patients.
The formulation in question combines estradiol, estriol, progesterone, and testosterone in a slow-release capsule, which is designed to provide a controlled release of hormones over an extended period. This combination of hormones is often used in hormone replacement therapy (HRT) to alleviate symptoms associated with menopause, such as hot flashes, vaginal dryness, and bone loss, as well as to address hormonal imbalances in both men and women. The use of Methocel E4M ensures that the hormones are released slowly, which can help in maintaining stable hormone levels and minimizing fluctuations that could lead to side effects or reduced efficacy.
When considering drug interactions, it is important to note that each hormone in this formulation can interact with other medications. Estradiol and estriol, both forms of estrogen, can potentially interact with thyroid hormone replacement therapy, as estrogens may increase thyroid-binding globulin (TBG) levels, thereby reducing the amount of thyroid hormone available. Patients on thyroid replacement therapy may require monitoring and possible dose adjustments. Estrogens can also reduce the clearance of certain benzodiazepines and tricyclic antidepressants, leading to increased effects or side effects of these drugs. Additionally, estrogens may interfere with the metabolism of drugs that are substrates of cytochrome P450 enzymes, particularly CYP3A4, such as certain statins, calcium channel blockers, and protease inhibitors.
Progesterone can interact with drugs that induce or inhibit hepatic enzymes, particularly CYP3A4. For example, certain anticonvulsants and antimicrobial agents can increase the metabolism of progesterone, potentially reducing its effectiveness. Conversely, inhibitors of CYP3A4 may increase progesterone levels, increasing the risk of side effects. Progesterone may also interact with benzodiazepines and other central nervous system depressants, potentially leading to increased sedation.
Testosterone interactions are also important to consider. Testosterone can affect blood glucose levels, and therefore, it may alter the effects of insulin or other antidiabetic medications, necessitating dose adjustments. Additionally, testosterone can increase the anticoagulant effects of warfarin and other blood thinners, which may require close monitoring of coagulation parameters and possible dose adjustments of the anticoagulant.
It is crucial for prescribers to review all medications, including over-the-counter drugs and herbal supplements, that a patient is taking to identify potential interactions with this hormone formulation. Adjustments to therapy or additional monitoring may be necessary to ensure safety and efficacy. Patients should be advised to inform their healthcare provider of any changes in their medication regimen, including the initiation or discontinuation of any drugs or supplements.
For more detailed information on potential drug interactions or specific concerns regarding this formulation, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is available to provide the necessary support and guidance to both patients and prescribers to ensure safe and appropriate use of this medication.
The formulation of Estradiol 0.4 mg/Estriol 1.6 mg/Progesterone 50 mg/Testosterone 3 mg Slow Release (MEM4) Oral Capsules is a compounded bioidentical hormone replacement therapy (BHRT) designed to mimic the body's natural hormonal rhythms and provide relief from symptoms associated with hormonal imbalances or deficiencies. Each of the hormones in this formulation plays a crucial role in managing various physiological functions, and their combination is tailored to address specific needs of the patient.
Estradiol is a form of estrogen, a female hormone involved in the reproductive system and the maintenance of secondary sexual characteristics. It is often prescribed to alleviate symptoms of menopause such as hot flashes, vaginal dryness, and osteoporosis prevention. Estriol, another form of estrogen, is considered to be weaker than estradiol but is included to provide a broader spectrum of estrogenic activity, potentially reducing the risk of estrogen-related side effects.
Progesterone is included to balance the effects of estrogen and is essential for regulating the menstrual cycle and maintaining the early stages of pregnancy. It can help prevent endometrial hyperplasia, which can occur when estrogen is taken without progesterone. Testosterone, although typically considered a male hormone, is also important in females for bone strength, brain function, and the maintenance of libido.
The use of Methocel E4M (hydroxypropyl methylcellulose) in this formulation is critical for the slow release mechanism. Methocel E4M is a high-viscosity grade of cellulose ether, which forms a gel-like matrix when it comes into contact with gastric fluids. This matrix creates a barrier that controls the rate at which the active ingredients are released from the capsule and absorbed into the bloodstream. The slow release of hormones provided by Methocel E4M allows for a more consistent serum hormone level, reducing the peaks and troughs associated with immediate-release formulations. This can lead to improved symptom control and a reduction in potential side effects.
By using this controlled-release technology, the formulation offers several benefits over traditional hormone replacement therapies. Patients may experience fewer side effects due to the steady release of hormones, and the reduced dosing frequency can enhance compliance with the treatment regimen. This is particularly beneficial for patients who may have difficulty adhering to multiple daily dosing schedules.
This compounded formulation is typically used to treat symptoms of menopause, perimenopause, and other hormonal imbalances. It may also be used in certain cases of androgen deficiency or to complement other treatments in conditions such as premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and certain forms of infertility. As with any medication, it is essential to tailor the therapy to the individual patient's needs, and this formulation allows for customization of hormone dosages.
It is important to note that hormone replacement therapy should be used with caution and under the supervision of a healthcare provider. Patients and prescribers considering this formulation should discuss the potential risks and benefits, as well as any contraindications or interactions with other medications. For more detailed information or if you have any questions regarding this formulation, please reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide guidance and support to ensure the safe and appropriate use of this medication.
MEM4 Oral Capsules is a compounded formulation that includes Estradiol 0.4 mg, Estriol 1.6 mg, Progesterone 50 mg, and Testosterone 3 mg. It's designed to deliver hormone replacement therapy in a slow-release capsule form using Methocel E4M, a controlled-release polymer.
MEM4 Oral Capsules utilize Methocel E4M, which is a controlled-release polymer. This polymer swells when it comes in contact with gastric fluids, forming a gel matrix that controls the rate at which the active hormones are released into the body, allowing for a gradual and extended release over time.
The slow-release formulation of MEM4 Oral Capsules offers several benefits, including sustained therapeutic levels of the medication throughout the day, reduced dosing frequency, minimized peaks and troughs in hormone levels, and improved patient compliance thanks to the convenience of less frequent dosing.
MEM4 Oral Capsules may be prescribed to individuals who require hormonal replacement therapy, particularly if they need a customized dosage of Estradiol, Estriol, Progesterone, and Testosterone. It is important that a healthcare provider evaluates the patient's hormonal needs before prescribing this formulation.
The dosing frequency for MEM4 Oral Capsules can vary based on individual patient needs and the advice of a healthcare provider. Due to the controlled-release design, the dosing may be less frequent compared to immediate-release hormone formulations. Always follow the specific dosing instructions provided by your healthcare professional.
As with any hormone replacement therapy, MEM4 Oral Capsules may cause side effects. These can vary depending on the individual and the specific hormones. Common side effects might include nausea, weight changes, mood swings, or changes in libido. If you experience any severe or concerning symptoms, contact your doctor immediately.
MEM4 Oral Capsules are typically not recommended for use during pregnancy. The hormones in this formulation can affect fetal development. If you become pregnant or plan to become pregnant while taking this medication, consult with your healthcare provider immediately for guidance.
MEM4 Oral Capsules should be stored at room temperature away from direct sunlight, moisture, and heat. Keep the capsules in their original container until it is time to take them, and make sure the container is tightly closed when not in use. Keep out of reach of children and pets.
It's possible that MEM4 Oral Capsules may interact with other medications. Therefore, it is important to inform your healthcare provider about all the medications you are taking, including over-the-counter drugs, supplements, and herbs. Your doctor will be able to determine if MEM4 is compatible with your other treatments.
If you miss a dose of MEM4 Oral Capsules, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and proceed with your regular dosing schedule. Do not take an extra capsule to make up for a missed dose. Consult your healthcare provider for specific guidance.
Yes, regular check-ups with your healthcare provider are critical when on any hormone replacement therapy, including MEM4 Oral Capsules. These check-ups allow your provider to monitor your hormone levels, adjust your dosage if needed, and check for any potential side effects.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
